文献速递医学人工智能与信息学临床试验与 GCP

临床决策支持系统对急性缺血性卒中诊疗质量与结局的影响:GOLDEN BRIDGE II 整群随机临床试验

Effect of a clinical decision support system on stroke care quality and outcomes in patients with acute ischaemic stroke (GOLDEN BRIDGE II): cluster randomised clinical trial.
PubMed 文献 · BMJ · 2026-03-20

干预组3个月新发血管事件为2.9%,低于对照组的3.9%(校正HR 0.74,95%CI 0.58–0.93,P=0.01),且诊疗质量复合指标更高。结论认为CDSS可降低新发血管事件并改善卒中诊疗质量。

要点

  • 卒中CDSS可降低急性缺血性卒中患者3个月新发血管事件风险(校正HR 0.74)。
  • CDSS组循证诊疗质量复合指标更高(91.4% vs 89.8%,校正OR 1.21)。
  • 残疾与全因死亡率未见显著差异,出血安全性事件无显著差异。

核心结论

  • 在中国急性缺血性卒中患者中使用卒中CDSS可显著降低3个月新发血管事件,并改善卒中诊疗质量、降低远期血管事件。

主要发现

  • 整群水平分析显示CDSS干预效应仍显著(-0.01,95%CI -0.02至-0.004,P=0.003)。
  • 残疾与全因死亡率、中度或重度出血及所有出血事件两组间无显著差异。

关键数值与推荐

  • 干预组医院接受卒中CDSS支持,包括人工智能辅助影像分析、卒中病因分型及循证治疗推荐;对照组接受常规诊疗。

临床怎么用

  • 在急性缺血性卒中诊疗中可考虑部署卒中CDSS以提升循证诊疗质量并降低新发血管事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy of a clinical decision support system (CDSS) on stroke care quality and clinical outcomes among patients with acute ischaemic stroke. DESIGN: Multicentre, cluster randomised clinical trial. SETTING: 77 hospitals across China. PARTICIPANTS: 77 hospitals (38 randomised to intervention group, 39 to control group) enrolled 21 603 patients with acute ischaemic stroke admitted to hospital within seven days after symptom onset. INTERVENTIONS: Hospitals in the intervention group received stroke CDSS support including artificial intelligence assisted imaging analysis, classification of stroke causes, and evidence based treatment recommendations. Hospitals in the control group provided usual care. MAIN OUTCOMES MEASURES: The primary outcome was a new vascular event (composite of ischaemic stroke, haemorrhagic stroke, myocardial infarction, and vascular death) within three months after initial symptom onset. Secondary outcomes included the composite measure and all-or-none measure of evidence based performance measures for acute ischaemic stroke care quality, a new vascular event at six and 12 months, and disability (modified Rankin Scale score 3-6) and all cause mortality at three, six, and 12 months. Safety outcomes were moderate or severe bleeding events and all bleeding events at three, six, and 12 months. RESULTS: 11 054 patients in the intervention group and 10 549 patients in the control group were enrolled from January 2021 to June 2023. New vascular events at three months occurred in 2.9% (320/11 054) in the intervention group compared with 3.9% (416/10 549) in the control group (adjusted hazard ratio 0.74, 95% confidence interval (CI) 0.58 to 0.93, P=0.01). The CDSS intervention effect remained significant in the cluster level analysis (-0.01, -0.02 to -0.004, P=0.003). Patients in the intervention group were more likely to have a higher composite measure (91.4% (77 049/84 276) v 89.8% (70 794/78 834), adjusted odds ratio 1.21, 95% CI 1.17 to 1.26, P<0.001). New vascular events were significantly lower in the intervention group at 12 months (4.0% (440/11 054) v 5.5% (576/10 549), adjusted hazard ratio 0.73, 95% CI 0.56 to 0.95, P=0.02). No significant differences were found in disability and all cause mortality. Moderate or severe bleeding, and all bleeding did not differ significantly between the two groups. CONCLUSIONS: Use of the stroke CDSS in patients with acute ischaemic stroke in China led to a significant decrease in new vascular events at three months. The stroke CDSS intervention was also effective in improving stroke care quality and decreasing long term vascular events. TRIAL REGISTRATION: ClinicalTrials.gov NCT04524624.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Zhang X, Ding L, Jing J, et al. Effect of a clinical decision support system on stroke care quality and outcomes in patients with acute ischaemic stroke (GOLDEN BRIDGE II): cluster randomised clinical trial. BMJ. 2026. PMID: 41862204. doi:10.1136/bmj-2025-085810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。